Cargando…
N-acetyl Cysteine Use in the Treatment of Shock Liver
Acute liver failure is a rare, life-threatening illness accounting for about 7% of all liver-related deaths. Patients with acute liver failure are managed with supportive care initially, and if supportive care fails, liver transplantation is the definitive option for eligible candidates in liver fai...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108670/ https://www.ncbi.nlm.nih.gov/pubmed/32257694 http://dx.doi.org/10.7759/cureus.7149 |
_version_ | 1783512820599488512 |
---|---|
author | Parvataneni, Swetha Vemuri-Reddy, Sireesha |
author_facet | Parvataneni, Swetha Vemuri-Reddy, Sireesha |
author_sort | Parvataneni, Swetha |
collection | PubMed |
description | Acute liver failure is a rare, life-threatening illness accounting for about 7% of all liver-related deaths. Patients with acute liver failure are managed with supportive care initially, and if supportive care fails, liver transplantation is the definitive option for eligible candidates in liver failure. N-acetyl cysteine (NAC) has a well-established role in acetaminophen-induced liver failure and has been reported to reduce mortality in these patients. It has also been reported to provide benefit in non-acetaminophen-induced liver failure secondary to infection, drugs, and toxins. Here we report an interesting case of NAC use in an elderly patient with shock liver secondary to severe sepsis in whom liver transplantation was not an option. |
format | Online Article Text |
id | pubmed-7108670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-71086702020-04-02 N-acetyl Cysteine Use in the Treatment of Shock Liver Parvataneni, Swetha Vemuri-Reddy, Sireesha Cureus Internal Medicine Acute liver failure is a rare, life-threatening illness accounting for about 7% of all liver-related deaths. Patients with acute liver failure are managed with supportive care initially, and if supportive care fails, liver transplantation is the definitive option for eligible candidates in liver failure. N-acetyl cysteine (NAC) has a well-established role in acetaminophen-induced liver failure and has been reported to reduce mortality in these patients. It has also been reported to provide benefit in non-acetaminophen-induced liver failure secondary to infection, drugs, and toxins. Here we report an interesting case of NAC use in an elderly patient with shock liver secondary to severe sepsis in whom liver transplantation was not an option. Cureus 2020-02-29 /pmc/articles/PMC7108670/ /pubmed/32257694 http://dx.doi.org/10.7759/cureus.7149 Text en Copyright © 2020, Parvataneni et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Parvataneni, Swetha Vemuri-Reddy, Sireesha N-acetyl Cysteine Use in the Treatment of Shock Liver |
title | N-acetyl Cysteine Use in the Treatment of Shock Liver |
title_full | N-acetyl Cysteine Use in the Treatment of Shock Liver |
title_fullStr | N-acetyl Cysteine Use in the Treatment of Shock Liver |
title_full_unstemmed | N-acetyl Cysteine Use in the Treatment of Shock Liver |
title_short | N-acetyl Cysteine Use in the Treatment of Shock Liver |
title_sort | n-acetyl cysteine use in the treatment of shock liver |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108670/ https://www.ncbi.nlm.nih.gov/pubmed/32257694 http://dx.doi.org/10.7759/cureus.7149 |
work_keys_str_mv | AT parvataneniswetha nacetylcysteineuseinthetreatmentofshockliver AT vemurireddysireesha nacetylcysteineuseinthetreatmentofshockliver |